

ASX RELEASE

21 September 2017

Managing Director to Present at Biotech in Europe Forum

MMJ PhytoTech Limited (ASX: MMJ) (“**MMJ**” or “**the Company**”) is pleased to advise that Managing Director Andreas Gedeon will be addressing the 17th Annual Biotech in Europe Forum which will be held on 26th-27th September 2017 at the Congress Center Basel in Switzerland.

Mr Gedeon has been invited to participate as a Speaker on the ‘*Medical Cannabis and Opportunities in Europe*’ panel, which will take place on Tuesday 26th September.

The event attracts a cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. The forum is recognised as a leading international platform for those interested in investing and partnering in the biotech and life science industry.

The panel will last approximately 45 minutes, and will include a brief presentation by each speaker, a roundtable discussion and audience Q&A.

– ENDS –

For media and investor inquiries please contact:

Andreas Gedeon
Managing Director
+1 (250) 713 6302
agedeon@mmj.ca

Released through Sam Burns, Six Degrees Investor Relations, M: +61 400 164 067



Follow us on Twitter @MMJPhytoTechLtd

<http://www.mmjphytotech.com.au>

About MMJ PhytoTech Limited

MMJ PhytoTech Limited (ASX: MMJ) is focused on becoming a large-scale cannabis producer, targeting direct supply to the growing Canadian medical and recreational markets which will have an estimated combined value of C\$8-9 billion by 2024. The Company controls operations across the entire medicinal cannabis value chain through its ~60% interest in TSX-V listed **Harvest One Cannabis Inc** (TSXV: HVST) and its 100% interest in Israeli research and development subsidiary, **PhytoTech Therapeutics Ltd**, both of which are strategically located in favourable jurisdictions with supportive regulatory frameworks in place.

ASX RELEASE

About Harvest One Cannabis Inc.

Harvest One Cannabis Inc. (TSXV: HVST) controls operations across the entire cannabis value chain through three business units, with Harvest One serving as the umbrella company over horticultural arm United Greeneries and medical arm Satipharm AG. Each business is strategically located in favourable jurisdictions with supportive regulatory frameworks in place. United Greeneries has received a Canadian medicinal cannabis cultivation licence, making Harvest One one of only a few companies globally with the capacity to commercially cultivate cannabis in a federally regulated environment.